(CEPH) Cephalon Drug Gains on Positive Data

Cephalon, Inc. (CEPH) oncology product Treanda could see a significant rise in demand thanks to encouraging data presented at the recently conducted annual meeting of the American Society of Hematology (ASH). Clinical data supporting the use of Treanda as a new standard of care in the first-line treatment of non-Hodgkin’s lymphoma (NHL) was presented at ASH. Data from an investigator-led proof-of-concept study demonstrated that newly diagnosed NHL patients who were treated with a combination of Treanda and Roche/Genentech‘s Rituxan experienced superior progression-free survival (55 months) compared to patients treated with the current standard of care, Rituxan plus a chemotherapy cocktail known as CHOP (35 months). The Rituxan-Treanda therapy was also found to be safer, less toxic and better tolerated. Treanda is currently approved for the treatment of patients suffering from